Fall Clinical Trials

254 recruitingLast updated: June 6, 2026

There are 254 actively recruiting fall clinical trials across 52 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Fall Trials at a Glance

254 actively recruiting trials for fall are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 91 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running fall studies include Mayo Clinic, M.D. Anderson Cancer Center, and AbbVie.

Treatments under study

About Fall Clinical Trials

Looking for clinical trials for Fall? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fall trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fall clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 254 trials

Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube CancerOvary CancerPeritoneal Cancer
University of Colorado, Denver53 enrolled5 locationsNCT05887609
Recruiting
Phase 1

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver50 enrolled2 locationsNCT06856499
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting

"Balance, Gait, and Motion Analysis in Multiple Sclerosis"

PhysiotherapyFatigueMultiple Sclerosis+7 more
University of Patras40 enrolled2 locationsNCT07630311
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

Ovarian CancerCervical CancerEndometrial Cancer+5 more
Aesculap AG132 enrolled2 locationsNCT06024109
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Gynecologic CancersFallopian Tube CancerPlatinum-sensitive Ovarian Cancer+1 more
AbbVie377 enrolled16 locationsNCT07024784
Recruiting
Phase 2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Endometrial CancerPlatinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+8 more
MacroGenics80 enrolled16 locationsNCT06730347
Recruiting
Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled168 locationsNCT06824467
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled64 locationsNCT06890338
Recruiting
Phase 3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled259 locationsNCT07213804
Recruiting

Assessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient

Tetrology of Fallot
Boston Children's Hospital40 enrolled1 locationNCT07184476
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2

Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07617753
Recruiting

Falls Validation Study

FallsIntracranial Bleed
Dr. Kerstin de Wit4,000 enrolled7 locationsNCT07536906
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Primary Peritoneal CancerFallopian Tube CancersAdvanced High-Grade Epithelial Ovarian Cancer
AbbVie110 enrolled52 locationsNCT06682988
Recruiting
Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled52 locationsNCT06787612